89Zr-APOMAB

N/A

Report date: 2025/09/24 16:00:59

Base Information

Drug Name89Zr-APOMAB

Drug Alias Name89Zirconium labeled chDAB4 antibody (Central Adelaide Local Health Network Inc)89Zirconium labeled-APOMAB

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedRadiation-emitting products > Nuclides > Zirconium > 89ZrRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionPositron-emission tomography enhancers

TargetsUpdating

Therapy Area/IndicationsSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell LungOvarian Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia and New Zealand

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesRoyal Adelaide Hospital, Adelaide

China Registration ClassN/A

Develop Information

Active CompaniesRoyal Adelaide Hospital, Adelaide

Inactive CompaniesN/A

Active IndicationsSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell LungOvarian Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A